Resveratrol (trans-3,4N-trihydroxystilbene), a phytoalexin present in grapes and red wine is emerging as a natural compound with anticancer properties. However, the physiological and molecular effects of resveratrol on normal uterine cells are poorly understood. In the present study we evaluated the effects of resveratrol on normal uterine cells and the mechanisms involved in vivo. Healthy immature rats were treated s.c. with resveratrol (0, 0.5, 5, and 50 mg/kg body weight) for 7 consecutive days and euthanized on the eighth day. Uteri were collected and weighed, and endometrium was recovered for total protein extraction, followed by Western blot analysis. Estrogen receptor alpha 1 (ESR1) and beta 2 (ESR2) affinity and activation by resveratrol were also determined by in vitro ESRbinding assays. Immunohistochemistry (IHC) studies were performed to visualize the proliferation marker, proliferating cell nuclear antigen (PCNA), and immunofluorescence (IF) studies were done to study the localization of PTGS2. The results showed that resveratrol increased uterine wet weight and uterine body weight ratios significantly. This local cellular proliferation in terms of the thickening of the columnar epithelial cells and an increase in the number of glands was accompanied by an increase of AKT 16 phosphorylation and PTGS2 and XIAP protein expression. These results were further supported by IF and IHC analyses. Total AKT, ESR1, and ESR2 protein expression levels were not modulated by the treatment; however, resveratrol showed moderate estrogenicity for both ESR isoforms. Expression of progesterone receptor A (PGR) was induced in the presence of resveratrol. These data support the hypothesis that resveratrol can act in a prosurvival or antiapoptotic way through AKT, XIAP, and PTGS2 regulation in the endometrium and could positively affect the outcome of pregnancy and favor fertility.
INTRODUCTION
Resveratrol (trans-3,4N-trihydroxystilbene) is a phytoestrogen present in grapes, peanuts, berries, pine nuts, plums, and red wine [1] . It has been emerging as a natural compound with anticancer properties [2] and has attracted the widespread attention of cancer prevention and treatment researchers. The antitumor activities of resveratrol are mediated through several cell signaling pathways and include cell arrest, suppression of tumor cell proliferation, and induction of apoptosis and differentiation [3, 4] . Phytoestrogens are dietary nonsteroidal compounds that have been speculated to offer protection against estrogen-dependant breast cancer and heart disease. A decreased incidence of breast cancer has been observed in Asian women who consume a high soya diet containing a significant amount of phytoestrogens [5] .
We have shown in previous studies that resveratrol can modulate PTGS2 and AKT expressions and activities in endometrial cancer cells and thus reverse cellular resistance associated with overexpression of these proteins [6] . PTGS2 overexpression is associated with tumorigenesis in animal models, and inhibition of the PTGS2 pathway has been associated with reduction in tumor incidence and progression of cancer [7] . The inhibition of PTGS2 activity is relevant to cancer chemotherapy because PTGS catalyzes the conversion of arachidonic acid to proinflammatory substances such as prostaglandins (PGs). The enhanced synthesis of PGs can favor the growth of malignant cells by increasing cell proliferation [8] . Studies of ligand binding to estrogen receptor alpha 1 (ESR1) and beta 2 (ESR2) showed that both ESR subtypes bind steroid hormones as well as phytoestrogens such as resveratrol [9] . It has been reported that postnatal exposure to resveratrol may affect estrogenic activity in specific peripheral tissues (e.g., gonads) and that resveratrol differs from most other phytoestrogens by acting as a possibly mixed ESR agonist/antagonist, depending on the tissue-specific availability of ESR subtypes [10] . Exposure to chemicals with estrogenic activity during critical stages of growth can interfere with the development and differentiation of an estrogen target organ [11] . The similarity in structure between resveratrol and the synthetic estrogen prompted us to investigate whether resveratrol might exhibit estrogenic activity in normal uterine cells.
The effects of estrogenic chemicals, e.g., resveratrol, on reproductive organs at crucial stages of development are a matter of concern. As ESR plays an important role in cell proliferation and differentiation, disruption of the ER signaling pathways may contribute to infertility, developmental abnormalities, or endocrine-related cancer both in animals and humans. This endocrine disruption could be linked to exposure to compounds with estrogenic or antiestrogenic activities [12] . Resveratrol exerts its anticancerous properties by antiproliferative and proapoptotic activities in various cancer cell types [13, 14] , but its molecular effect on uterine cells, both normal and cancerous, is poorly documented. To elucidate further the mechanisms of resveratrol in normal endometrial cells, the present study was designed to investigate in vivo if the resveratrol protective effect would also involve PTGS2 and AKT pathways and/or ESR.
MATERIALS AND METHODS

Reagents
Resveratrol (trans-3,4N-trihydroxystilbene) was obtained from Sigma (St. Louis, MO). Phospho-AKT Ser473 (catalog no. 9271), AKT (catalog no. 9272), PR-A (catalog no. 3172), proliferating cell nuclear antigen (PCNA; catalog no. 2586), and XIAP (catalog no. 2042) antibodies were obtained from Cell Signaling Technology (Beverly, MA). b-Actin (catalog no. A3854) antibody was purchased from Sigma-Aldrich (St. Louis, MO). PTGS1 (catalog no. 160109) and PTGS2 (catalog no. 160126) antibodies were obtained from Cayman Chemical (Ann Arbor, MI). ESR1 (catalog no. Ab 15) was purchased from NeoMarker (Fremont, CA). ESR2 (catalog no. GR39) antibody was purchased from Calbiochem (San Diego, CA). Protease inhibitor cocktail tablets were procured from Roche (Laval, QC). Secondary horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse immunoglobulin G (IgG) antibody were purchased from Bio-Rad (Mississauga, ON). Secondary HRP-conjugated anti-mouse IgM antibody was from Calbiochem (San Diego, CA).
Animals
Immature Sprague-Dawley female rats (35-50 g) were obtained from Charles River Laboratories, Canada. Animals were maintained on standard chow and water, which were available ad libitum, in animal facilities illuminated on a normal 12-h cycle. All procedures were performed in accordance with guidelines of the Canadian Council on Animal Care for the handling and training of laboratory animals and the Good Health and Animal Care Committee of the Université du Québec à Trois-Rivières. Rats were sacrificed after the treatment period was completed, and uteri were collected.
Resveratrol Treatment
Animals were divided into four groups with eight rats per group. Healthy immature Sprague-Dawley rats were treated s.c. with resveratrol dissolved in 10% ethanol (0, 0.5, 5, 50 mg/kg body weight [BW]) for 7 consecutive days and euthanized on the eighth day. Control group (0 mg/kg BW) received equal amounts of vehicle.
Uterine Wet Weights
After resveratrol treatment, uterine tissues were excised, and all connective tissue was removed prior to wet weight recordings. The actual uterine weight, in grams (g), was divided by actual BW of the rat and multiplied by a standard body weight of 80 g.
Protein Extraction and Western Analysis
Tissue from each uterus was minced and homogenized in radioimmunoprecipitation assay lysis buffer (PBS 13, pH 7.4; 1% Nonidet P-40; 0.5% sodium deoxycholate; 0.1% SDS; protease inhibitor cocktail tablets). Homogenates were sonicated and centrifuged (12 000 3 g for 20 min at 48C) to remove insoluble material. The supernatant was recovered and stored at À208C pending analyses. Protein content was determined with the Bio-Rad detergent compatible protein assay. Protein extracts (50 lg) were heated (958C, 3 min), resolved by 10% SDS-polyacrylamide gel electrophoresis and electrotransferred to nitrocellulose membranes (15 V, 30 min), using a semidry transfer (Bio-Rad, Mississauga, ON). The membranes were then blocked 1 h at room temperature with PBS-Tween 20 0.06% containing 5% nonfat milk powder and then incubated (overnight, 48C) with AKT (1:2000); pAKT (1:750); PTGS1 (1:750); PTGS2 (1:750); ESR1 (1:500); ESR2 (1:7500); progesterone receptor A (PGR) (1:1000); and XIAP (1:1500) antibody and subsequently with HRP-conjugated anti-rabbit or anti-mouse secondary antibody (1:3000; room temperature for 45 min). All membranes were reprobed with an antibody specific to b-actin (1:50 000), which was used as an internal standard. Densitometric analyses were performed on both images (protein of interest and b-actin), using the GelDoc 2000 and the Quantity One software (Bio-Rad, Mississauga, ON). Results are expressed as a ratio of protein of interest:b-actin to correct for loading for each endometrial sample.
ESR Binding Affinity
The ESR alpha and beta (ESR1 and ESR2, respectively) affinity assay was performed using recombinant hERa and hERb (Calbiochem/EMD BioSciences, Darmstadt, Germany) and a HitHunter enzyme fragment complementary (EFC) ESR assay kit (DiscoveRx Corp., Fremont, CA) according to manufacturer's protocol [15] . HitHunter EFC technology is based on a genetically engineered b-galactosidase (b-gal) enzyme that consists of two fragments termed enzyme acceptor (EA) and enzyme donor (ED). Briefly, different concentrations of estrogen analogs were added to wells containing ESR plus ED in a 96-well black plate. Incubation provided competition for the ESR binding against labeled ED-ES hormone conjugate, a small peptide fragment of b-gal. Then, EA, an inactive b-gal protein fragment, and a fluorescent substrate were added to each well. Unbound ED-ES bind to EA to form an active enzyme, which subsequently hydrolyzes the fluorescent substrate for EFC detection by a microplate reader (FLUOStar OPTIMA; BMG Labtech, Offenburg, Germany). The excitation wave is 530 nm, and luminosity is detected at 620 nm. The amount of free ED conjugate in the assay is proportional to the concentration of estrogen analogs bound to the ESR [15] . A standard curve of 17b-estradiol was run in parallel. All assays were done in triplicate.
Immunofluorescence and Hematoxylin and Eosin Staining
The uterus was fixed in 4% paraformaldehyde solution and embedded in paraffin. Tissue sections of 7-lm thickness were mounted on polylysine-coated slides. The slides were deparaffinized by heating at 608C for 30 min, followed by two washes in NeoClear solvent (VWR Canlab, Mississauga, ON), and then progressively hydrated with successive washes at room temperature in 100% ethanol, 95% ethanol in PBS, and 70% ethanol in PBS, and followed by a wash in PBS. After permeabilization for 6 min in boiling citrate solution (0.1% sodium citrate, 0.1% Triton X-100 in water), the tissue slides were washed FIG. 1. A) Effect of resveratrol (0, 0.5, 5, and 50 mg/kg daily for 7 days) on total rat body weight is shown. Relative weights are presented as percentages of weight on Day 0 of the experiment for each rat. RES, resveratrol. B) Uterine wet weight was standardized to rat body weight. Each group represents means 6 SEM of eight different uteri. Different letters are significant (P , 0.05).
twice with PBS at room temperature. Nonspecific binding sites were blocked by 1-h incubation with 2% bovine serum at room temperature in a humidified chamber, and the tissues were probed with mouse anti-PTGS2 primary antibody diluted in blocking serum, 1:100, overnight at 48C. The slides were washed twice with PBS, and the tissues were probed with Alexa Fluor 488-conjugated anti-rabbit secondary antibody diluted 1:200 (Cell Signaling Technology) for 1 h at room temperature in a humidified chamber protected from light. The slides were washed once with PBS and counterstained with Hoechst nuclear dye, followed by two rinses with water. The tissues were covered with 0.1% para-phenylenediamine as antifading agent and observed under a fluorescence microscope. Negative controls were treated using the same protocol but substituting the primary antibody with rabbit anti-GST primary antibody (Cell Signaling Technology).
Tissues were rehydrated by washing with graded ethanol, followed by washing with PBS. Sections were stained with hematoxylin and eosin (H&E), using standard protocol for staining. Tissue sections were examined for morphological changes in uterus. For each animal, six random tissue sections (five fields per section) were examined. Glands were counted blindly, and stromal thickness was measured at six different regions, using measurement tool of Adobe Photoshop CS5 software. Stained tissues were viewed under a Olympus BX60 microscope (Olympus, Tokyo, Japan).
PCNA Immunostaining
Paraffin-embedded tissues were deparaffinized by heating at 608C for 30 min. We followed the same procedure to hydrate the tissues as for immunofluorescence. After permeabilization for 10 min in boiling citrate solution (10 mM sodium citrate, 0.05 Tween 20 in water, pH 6.0), the tissue slides were washed twice with PBS at room temperature. Endogenous peroxidase activity was blocked by keeping the slides in peroxide block as provided with kit from DakoCytomation LSAB2 system-HRP for 30 min at room temperature. A nonimmune block was then carried out by incubating the tissues with protein block (serum free) 30 min at room temperature. Sections were then incubated with PCNA primary antibody (dilution 1:4000) for 1 h at room temperature. For negative control, primary antibody was replaced with normal mouse IgG, using the same dilution as for primary antibody. The biotinylated Link (DakoCytomation, Glostrup, Denmark) was applied to the sections as provided in the kit, followed by streptavidin-HRP. The peroxidase substrate diaminobenzidine tetrachloride was used to visualize the reaction. Slides were lightly counterstained with hematoxylin (1:1 in water) and were examined under the Olympus BX60 microscope (Olympus, Tokyo, Japan).
Statistical Analysis
Data were subjected to one-way ANOVA or Student t test (PRISM software version 4.0; GraphPad, San Diego, CA). Differences between experimental groups were determined by the Tukey test. Differences with a P value of ,0.05 were considered statistically significant.
RESULTS
Body and Uterine Weights
The results of BW and wet uterine weights are depicted in Figure 1 . Results showed that subcutaneous dose of 5 mg/kg BW of resveratrol increased uterine wet weight significantly (P FIG. 2. A) The effect of resveratrol (0, 0.5, 5, and 50 mg/kg daily for 7 days) on the levels of p-AKT, AKT, and XIAP in immature rat uterus was determined by Western blot analysis. b-Actin was used as a loading control. Densitometric analyses of protein expression in control and treated groups are shown below blots. Each group represents means 6 SEM of seven different uteri. Different letters are significant (P , 0.05).
, 0.05) compared to control group. This could be due to increased cellular proliferation upon treatment with resveratrol. However, the uterine wet weight was found to be decreased upon further increase in the dose (50 mg/kg BW) compared to the group treated with 5 mg/kg BW.
Effect of Resveratrol on p-AKT, Total AKT, and XIAP Protein Levels in Rat Uterus
Initial studies focused on the effect of resveratrol on the activation and phosphorylation of survival factors AKT and XIAP. Treatment of rats with 5 mg/kg BW of resveratrol increased AKT phosphorylation and XIAP expression in endometrial cells. Densitometric analysis of protein expression in control and treated groups are given in Figure 2 .
Effect of Resveratrol on PTGS1 and PTGS2 Protein Levels in Rat Uterus
Cyclooxygenase is the rate-limiting enzyme responsible for the synthesis of PGs. We next tested the modulation of PTGS1 and PTGS2 by resveratrol in rat uterus. The results demonstrate that there was no significant change in PTGS1 protein levels with the increasing dose of resveratrol (Fig. 3A) . However, treatment of rats with resveratrol led to a significant increase in PTGS2 levels at dose of 5 mg/kg BW of resveratrol (Fig. 3B) , while at higher dose of 50 mg/kg BW, resveratrol reduced the PTGS2 protein levels compared to the dose of 5 mg/kg BW.
Effect of Resveratrol on Progesterone and Estrogen Receptor Protein Levels in Rat Uterus and Estrogen Receptor Binding Affinity
Previously, resveratrol has been shown to function as an ESR agonist [16, 17] ; we further examined whether resveratrol could induce the expression of ESR and PGR in rat uterus. In the present study, resveratrol had no appreciable effect on the protein levels of both ESR1 and ESR2 (Fig. 4, A and B) . However, resveratrol induced PR-A protein levels significantly (Fig. 4C) . The highest expression of PGR was observed at the dose of 5.0 mg/kg BW. Furthermore, we tested estrogen binding affinity using recombinant hESR1 and hESR2 (Fig. 5) . Our results showed that resveratrol had moderate estrogenicity for both ESR isoforms, low binding-affinity/activation, favoring ESR2 compared to 4-OH-tamoxifen. Figure 6 depicts the results of immunofluorescence for tissue sections. PTGS2 was found to be localized to the apical surface of uterine epithelium, when rats were treated with resveratrol at dose of 5 mg/kg BW (Fig. 6D ) compared to control and 0.5 mg/kg BW groups (Fig 6, B and C) . In addition, PTGS2 expression was also observed in stroma of uterus. When rats were treated with 50 mg/kg BW of resveratrol, PTGS2 was largely localized to glandular and luminal epithelium (Fig. 6E) .
Immunohistochemistry and Morphological Studies
Histological studies (H&E staining) revealed that there were fewer glands with compact stroma and poorly developed epithelium in the control group. On the contrary, multiple glands were present in the uterine stroma, and stroma was more thickened in cases where rats were treated with resveratrol 5 mg/kg BW compared to the control group (Fig. 7) . Administration of resveratrol induced prominent changes in the endometrial luminal epithelium, as well as in the glandular epithelium. The luminal and glandular epithelium showed deeply stained epithelial cells at some places, characteristic of endometrial hyperplasia, resulting in greater gland-to-stroma ratio than in normal endometrium. We analyzed PCNA as a marker of proliferation in rat uterine tissues. The representative staining for each group including negative control are shown in Fig. 8 . PCNA immunohistochemical analysis revealed strong immunoreactivity in endometrial luminal epithelium in tissue sections from rat treated with resveratrol compared to the control group. The PCNA staining intensity was gradually increased in the endometrial luminal epithelium and in stroma in rats treated with increasing doses of resveratrol (Fig. 8) .
DISCUSSION
Previous studies have shown that resveratrol has promising pharmacological properties including anticarcinogenic, antiinflammatory, and cardio protection [18] [19] [20] . However, recently, resveratrol has been shown to act as a proliferative/ prosurvival agent in a cell-and tissue-specific manner [21] . The primary goal of the present study was to determine whether the protective effect of resveratrol involves AKT and/ or PTGS pathway. We have also determined the role of ESR/ PGR receptors in resveratrol's beneficial effect in immature rat endometrial cells. Our study indicates that when immature rats were treated with increasing dose of resveratrol, the uterine wet weight increased. These results are in accordance with previous reports where a low dose (0.1-1.0 mg/ml) of resveratrol promoted cellular proliferation [22] . To gain insights into the molecular mechanism involved in resveratrol's proliferative effect, we examined the levels of phosphorylated AKT, a key regulator of cell growth and survival. We found that the local cellular proliferation was accompanied by an increase of AKT phosphorylation and thereby its activation. We have previously demonstrated that the activity of AKT directly modulated survival/apoptosis in uterine cancer cells [23] . Similarly, AKT could be involved in regulating cell survival in normal uterine cells. Notably, an earlier study reported that resveratrol treatment induced the activation of JNK, MAPK14 (p38), AKT, and NFKB signaling pathways in breast cancer cells [21] . Our results also showed that in uterine cells, a high dose (50 mg/kg BW) of resveratrol decreased pAKT levels, which is consistent with the previous report from our laboratory [6] . In addition to AKT activation, we have also observed an induction of antiapoptotic XIAP levels upon treatment with resveratrol (5 mg/kg BW). However, XIAP levels decreased at the highest dose used in the study. This observations is in accordance with the previous report that resveratrol could enhance cell proliferation at a lower dose and may induce cell death at higher doses in normal and tumor cells [22] . Immunostaining is shown for negative control, where no green signal was detected. In case of negative control, primary antibody was replaced by normal rabbit IgG. B) Immunostaining is shown for control group (0 mg/kg daily). C) Immunostaining of resveratrol-treated group (0.5 mg/kg daily) is shown. D) Immunostaining of resveratrol-treated group (5 mg/kg daily) is shown. PTGS2 expression was more pronounced in apical surface of epithelial cells and also seen in stroma (E). Immunostaining resveratrol treatment group (50 mg/kg daily) PTGS2 was more localized to apical surface of epithelium rather than stroma. All the tissues were counterstained with Hoechst 33342 to stain nuclei (blue). Original magnification 3200. Different letters are significant (P , 0.05).
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The other observation presented here is that resveratrol treatment induced PTGS2 expression, which is clearly evident from immunofluorescence studies. PTGS2 levels were increased in tissue sections from rats treated with 5 mg/kg BW of resveratrol. This finding was in accordance with the previous study by Lin et al., in 2008 [24] . PTGS2 overexpression in cell and animal models has been associated with tumorigenesis, enhanced cellular adhesion, and inhibition of apoptosis [25, 26] . This observation also favors the role of resveratrol in increasing cellular proliferation, as discussed earlier for pAKT and XIAP. This was confirmed by the results of H&E staining, where it is clearly evident that numbers of glands were increased along with thickened luminal as well as glandular epithelium. PCNA immunohistochemical analysis further supports our results for increased proliferation in resveratroltreated rats compared to control rats, where the endometrial luminal epithelial showed strong PCNA immunoreactivity for resveratrol-treated rats. However, the expression of PTGS1 was not induced by resveratrol, and the levels were consistent at all the doses tested in the study. This further emphasizes its role as a constitutive enzyme in normal rat uterine cells [27] .
Resveratrol has been demonstrated as a chemopreventive and chemotherapeutic agent [28] and has been classified as a phytoestrogen because it binds to ESR1 with low affinity [17] . Here we tested the estrogen agonist/antagonist activity of resveratrol with ESR1 and ESR2 in normal uterine cells from immature rats. In addition, we evaluated the effect of resveratrol on the induction of PGR. We showed that resveratrol treatment significantly increased PGR protein levels. An earlier study by Gehm et al. [29] has shown that resveratrol binds to ESRs and activates estrogen-responsive genes in vitro. Moreover, the authors have shown that resveratrol produced greater transcriptional activation of 
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progesterone receptor than estradiol. Interestingly, in the present study, resveratrol had no noticeable effect on the protein levels of ESR1 and ESR2 isoforms. However, ligand binding studies demonstrated that resveratrol binds ESR1 and ESR2 with low binding affinity, favoring ESR2. This finding is in accordance with the previous study [9] showing that several phytoestrogens bind ESR2 with higher affinity than ESR1. This indicates that those tissues that uniquely express ESR2 or that express higher levels of ESR2 than ESR1 may be more sensitive to resveratrol's estrogen agonist activity. It is known that ESRs regulate cellular proliferation [30] . Therefore the increased tissue growth in our study could be due to resveratrol's affinity for ESRs. Indeed, it has also been reported that low concentrations of resveratrol could induce AKT phosphorylation in MCF-7 breast cancer cells, and this prosurvival effect is limited to cells expressing ESRs [31] . Taken together, the results of the present study suggest that at low dose, resveratrol might act as an agonist for specific ESRs, thereby leading to the activation of signaling pathways important for cell survival in the endometrium.
In conclusion, in normal rats in vivo, resveratrol can act as a prosurvival factor through the activation of AKT phosphorylation and downstream up-regulation of XIAP and PTGS2 expression, depending on the localization and the nature of the cells involved.
